Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/10/23
End: 07/12/23
Due: 07/12/24
Phase: N/A
Priority: Normal
Start: 12/16/22
End: 08/01/24
Due: 08/01/25
Phase: N/A
Priority: Normal
Start: 07/01/24
End: 02/29/28
Due: 02/28/29
Phase: N/A
Priority: Normal
Start: 05/25/21
End: 07/18/24
Due: 07/18/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) | NCT05641324 | Anaveon AG | user2@example.com | None | 2023-02-10 | 2023-07-12 | 2024-07-12 | - | - | 2025-07-14 |
| A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). | NCT05578872 | Anaveon AG | user2@example.com | None | 2022-12-16 | 2024-08-01 | 2025-08-01 | - | - | 2025-07-14 |
| A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1) | NCT06470763 | Anaveon AG | user2@example.com | None | 2024-07-01 | 2028-02-29 | 2029-02-28 | - | - | 2025-07-14 |
| A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer. | NCT04855929 | Anaveon AG | user2@example.com | None | 2021-05-25 | 2024-07-18 | 2025-07-18 | - | - | 2025-07-14 |